Neurogene to Participate in BMO Genetic Medicines Summit

Rhea-AI Summary

Neurogene (NASDAQ: NGNE), a clinical-stage company focused on developing genetic medicines for rare neurological diseases, announced its participation in the BMO 2024 Genetic Medicines Summit. The event will take place on Tuesday, July 9, at 8:30 a.m. ET. Neurogene's management will be involved in a panel discussion titled 'Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?' and will also engage in investor meetings. This participation underscores Neurogene's commitment to advancing gene therapy as a viable treatment option for rare diseases.

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit.

Format: Management will participate in the panel, “Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?” and participate in investor meetings
Date: Tuesday, July 9 at 8:30 a.m. ET

About Neurogene
The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and is expected to support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702497314/en/

Company:

Cara Mayfield

Vice President, Corporate Affairs

cara.mayfield@neurogene.com

Investor:

Melissa Forst

Argot Partners

Neurogene@argotpartners.co

Source: Neurogene Inc.

FAQ

What is Neurogene's stock symbol?

Neurogene's stock symbol is NASDAQ: NGNE.

When is Neurogene participating in the BMO Genetic Medicines Summit?

Neurogene is participating in the BMO Genetic Medicines Summit on Tuesday, July 9, at 8:30 a.m. ET.

What panel will Neurogene's management join at the BMO Summit?

Neurogene's management will join the panel titled 'Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?' at the BMO Summit.

What is the focus of the BMO 2024 Genetic Medicines Summit?

The BMO 2024 Genetic Medicines Summit focuses on discussions about the commercial viability of gene therapy for rare diseases.

Why is Neurogene's participation in the BMO Summit significant?

Neurogene's participation in the BMO Summit is significant as it highlights the company's commitment to advancing gene therapy for rare neurological diseases and engaging with the investor community.

Will Neurogene's management meet with investors at the BMO Summit?

Yes, Neurogene's management will participate in investor meetings at the BMO Genetic Medicines Summit.